The Week Ahead In Biotech (Nov. 21-Nov. 27)
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Among the major news of the week was $Pfizer(PFE.US)$ filing an application for emergency use authorization for its oral COVID-19 pill Paxlovid. The company also bagged a $5.29 billion contract from the U.S. government to supply the investigational antiviral treatment and announced a voluntary license agreement with a U.N.-backed body to facilitate greater access to the global population.
$Biogen(BIIB.US)$ was also in the news due to long-time company veteran and R&D head Alfred Sandrock, who oversaw the development of many breakthrough neurological treatments, announcing his retirement.
$Connect Biopharma(CNTB.US)$ came under intense selling pressure after what seemed like positive topline data from the Phase 2 study of its investigational therapy CBP-201 in atopic dermatitis. Lack of efficacy details from each arm of the study irked investors, as they could not weigh in vis-à-vis existing treatments.
On the other hand, $Longeveron(LGVN.US)$ shares nearly doubled during the week after its Lomecel-B for hypoplastic left heart syndrome drug received a rare pediatric disease designation from the Food and Drug Administration.
Moomoo is an app offered by Moomoo Technologies Inc. that provides information about investments. Moomoo Technologies is not an investment adviser or a broker-dealer and it provides neither investment or financial advice nor securities trading services. All contents such as comments and links posted or shared by users of the community are opinions of the respective authors only and do not reflect the opinions, views, or positions of Moomoo Technologies, its affiliates, or any employees of Moomoo Technologies or its affiliates. You are advised to consult a qualified financial or tax advisor for your personal financial planning and tax situations. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.
3 Comments · 47K Views